FDA APPROVES NUTROPIN AQ PEN FOR DELIVERY OF GROWTH HORMONE.(Genetech Inc.)

Biotech Equipment Update, June, 2002

Genentech, Inc. (NYSE:DNA), South San Francisco, has announced that the Nutropin AQ Pen(TM) has received clearance from the FDA. The Nutropin AQ Pen(TM) is designed for exclusive use with the Nutropin AQ Pen(TM) Cartridge (somatropin [rDNA origin] injection). Nutropin AQ(R) is indicated for the long- term treatment of growth failure in pediatric patients due to inadequate endogenous growth hormone (GH) secretion, for short stature associated with Turner's syndrome or chronic renal insufficiency (CRI) up to the time of renal transplantation, and as a replacement therapy in eligible ...